Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer

PierFranco Conte, Barbara Salvadori, Sara Donati, Elisabetta Landucci, Alessandra Gennari

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Strategies to improve outcome in metastatic breast cancer include the first-line use of combinations of optimal doses of active agents, with the goal being to improve complete response rates and thus long-term survival. Although prior studies of anthracycline/taxane combinations generally have shown improved response rates and progression-free survival in comparison with single-agent regimens or anthracycline/cyclophosphamide-containing combinations, the data have not consistently demonstrated improved overall survival; indeed, they have yielded generally disappointing complete response rates. We evaluated the combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN), epirubicin, and paclitaxel (GET) based on the hypothesis that epirubicin/paclitaxel is best suited for achieving delivery of optimal doses, and the addition of gemcitabine (which exhibits good single-agent activity with a favorable toxicity profile) will increase activity. In a phase II trial of 36 patients, the GET regimen produced reasonable toxicity and was associated with a 92% response rate, including complete responses in 31% of patients. The overall response rate increased to 97%, including complete responses in 41% of patients, with high-dose consolidation chemotherapy in 25 patients. A trial comparing GET with epirubicin/paclitaxel as first-line treatment in more than 600 patients with metastatic breast cancer has been initiated, with survival as the primary end point. Another large-scale trial is being planned to compare the GET regimen with an anthracycline/cyclophosphamide/paclitaxel combination in patients with early stage high-risk breast cancer.

Original languageEnglish
Pages (from-to)15-17
Number of pages3
JournalSeminars in Oncology
Volume28
Issue number2 SUPPL. 7
Publication statusPublished - 2001

Fingerprint

gemcitabine
Epirubicin
Paclitaxel
Breast Neoplasms
Anthracyclines
Cyclophosphamide
Survival
Consolidation Chemotherapy
Disease-Free Survival

ASJC Scopus subject areas

  • Oncology

Cite this

Conte, P., Salvadori, B., Donati, S., Landucci, E., & Gennari, A. (2001). Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Seminars in Oncology, 28(2 SUPPL. 7), 15-17.

Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. / Conte, PierFranco; Salvadori, Barbara; Donati, Sara; Landucci, Elisabetta; Gennari, Alessandra.

In: Seminars in Oncology, Vol. 28, No. 2 SUPPL. 7, 2001, p. 15-17.

Research output: Contribution to journalArticle

Conte, P, Salvadori, B, Donati, S, Landucci, E & Gennari, A 2001, 'Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer', Seminars in Oncology, vol. 28, no. 2 SUPPL. 7, pp. 15-17.
Conte P, Salvadori B, Donati S, Landucci E, Gennari A. Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. Seminars in Oncology. 2001;28(2 SUPPL. 7):15-17.
Conte, PierFranco ; Salvadori, Barbara ; Donati, Sara ; Landucci, Elisabetta ; Gennari, Alessandra. / Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer. In: Seminars in Oncology. 2001 ; Vol. 28, No. 2 SUPPL. 7. pp. 15-17.
@article{7753c43f368b467ca20e1a8d565ec5c0,
title = "Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer",
abstract = "Strategies to improve outcome in metastatic breast cancer include the first-line use of combinations of optimal doses of active agents, with the goal being to improve complete response rates and thus long-term survival. Although prior studies of anthracycline/taxane combinations generally have shown improved response rates and progression-free survival in comparison with single-agent regimens or anthracycline/cyclophosphamide-containing combinations, the data have not consistently demonstrated improved overall survival; indeed, they have yielded generally disappointing complete response rates. We evaluated the combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN), epirubicin, and paclitaxel (GET) based on the hypothesis that epirubicin/paclitaxel is best suited for achieving delivery of optimal doses, and the addition of gemcitabine (which exhibits good single-agent activity with a favorable toxicity profile) will increase activity. In a phase II trial of 36 patients, the GET regimen produced reasonable toxicity and was associated with a 92{\%} response rate, including complete responses in 31{\%} of patients. The overall response rate increased to 97{\%}, including complete responses in 41{\%} of patients, with high-dose consolidation chemotherapy in 25 patients. A trial comparing GET with epirubicin/paclitaxel as first-line treatment in more than 600 patients with metastatic breast cancer has been initiated, with survival as the primary end point. Another large-scale trial is being planned to compare the GET regimen with an anthracycline/cyclophosphamide/paclitaxel combination in patients with early stage high-risk breast cancer.",
author = "PierFranco Conte and Barbara Salvadori and Sara Donati and Elisabetta Landucci and Alessandra Gennari",
year = "2001",
language = "English",
volume = "28",
pages = "15--17",
journal = "Seminars in Oncology",
issn = "0093-7754",
publisher = "W.B. Saunders Ltd",
number = "2 SUPPL. 7",

}

TY - JOUR

T1 - Gemcitabine, epirubicin, and paclitaxel combinations in advanced breast cancer

AU - Conte, PierFranco

AU - Salvadori, Barbara

AU - Donati, Sara

AU - Landucci, Elisabetta

AU - Gennari, Alessandra

PY - 2001

Y1 - 2001

N2 - Strategies to improve outcome in metastatic breast cancer include the first-line use of combinations of optimal doses of active agents, with the goal being to improve complete response rates and thus long-term survival. Although prior studies of anthracycline/taxane combinations generally have shown improved response rates and progression-free survival in comparison with single-agent regimens or anthracycline/cyclophosphamide-containing combinations, the data have not consistently demonstrated improved overall survival; indeed, they have yielded generally disappointing complete response rates. We evaluated the combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN), epirubicin, and paclitaxel (GET) based on the hypothesis that epirubicin/paclitaxel is best suited for achieving delivery of optimal doses, and the addition of gemcitabine (which exhibits good single-agent activity with a favorable toxicity profile) will increase activity. In a phase II trial of 36 patients, the GET regimen produced reasonable toxicity and was associated with a 92% response rate, including complete responses in 31% of patients. The overall response rate increased to 97%, including complete responses in 41% of patients, with high-dose consolidation chemotherapy in 25 patients. A trial comparing GET with epirubicin/paclitaxel as first-line treatment in more than 600 patients with metastatic breast cancer has been initiated, with survival as the primary end point. Another large-scale trial is being planned to compare the GET regimen with an anthracycline/cyclophosphamide/paclitaxel combination in patients with early stage high-risk breast cancer.

AB - Strategies to improve outcome in metastatic breast cancer include the first-line use of combinations of optimal doses of active agents, with the goal being to improve complete response rates and thus long-term survival. Although prior studies of anthracycline/taxane combinations generally have shown improved response rates and progression-free survival in comparison with single-agent regimens or anthracycline/cyclophosphamide-containing combinations, the data have not consistently demonstrated improved overall survival; indeed, they have yielded generally disappointing complete response rates. We evaluated the combination of gemcitabine (Gemzar; Eli Lilly and Company, Indianapolis, IN), epirubicin, and paclitaxel (GET) based on the hypothesis that epirubicin/paclitaxel is best suited for achieving delivery of optimal doses, and the addition of gemcitabine (which exhibits good single-agent activity with a favorable toxicity profile) will increase activity. In a phase II trial of 36 patients, the GET regimen produced reasonable toxicity and was associated with a 92% response rate, including complete responses in 31% of patients. The overall response rate increased to 97%, including complete responses in 41% of patients, with high-dose consolidation chemotherapy in 25 patients. A trial comparing GET with epirubicin/paclitaxel as first-line treatment in more than 600 patients with metastatic breast cancer has been initiated, with survival as the primary end point. Another large-scale trial is being planned to compare the GET regimen with an anthracycline/cyclophosphamide/paclitaxel combination in patients with early stage high-risk breast cancer.

UR - http://www.scopus.com/inward/record.url?scp=0035015879&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035015879&partnerID=8YFLogxK

M3 - Article

VL - 28

SP - 15

EP - 17

JO - Seminars in Oncology

JF - Seminars in Oncology

SN - 0093-7754

IS - 2 SUPPL. 7

ER -